NASDAQ: FATE
Fate Therapeutics Inc Stock Ownership - Who owns Fate Therapeutics?

Insider buying vs selling

Have Fate Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Jerome Charles BressiChief Regulatory and Quality Officer2025-01-105,980$1.55
$9.27kSell
Cindy TahlChief Legal Compliance Officer and Secretary2025-01-105,654$1.55
$8.76kSell
Bahram ValamehrPresident and CEO2025-01-108,705$1.54
$13.41kSell
Redmile Group LLCDirector2024-12-20341,633$1.68
$573.94kSell
Redmile Group LLCDirector2024-12-20397,964$1.68
$668.58kBuy
Redmile Group LLCDirector2024-12-201,084,936$1.68
$1.82MSell
Redmile Group LLCDirector2024-12-201,084,936$1.68
$1.82MBuy
Yuan XuDirector2024-08-06633$4.23
$2.68kSell

1 of 1

FATE insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when FATE insiders and whales buy or sell their stock.

FATE Shareholders

What type of owners hold Fate Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Redmile Group LLC22.44%25,712,223$28.54MInsider
Redmile Group LLC11.23%12,872,946$14.29MInstitution
Blackrock Inc9.55%10,941,582$12.15MInstitution
Vanguard Group Inc9.02%10,333,033$11.47MInstitution
Amir Nashat8.60%9,852,967$10.94MInsider
Polaris Venture Management Co V LLC8.59%9,841,933$10.92MInsider
Bellevue Group Ag4.22%4,839,779$5.37MInstitution
Citadel Advisors LLC3.82%4,382,257$4.86MInstitution
Deerfield Management Company LP Series C3.10%3,555,871$3.95MInstitution
Johnson Johnson2.95%3,379,064$3.75MInstitution

1 of 3

FATE vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
FATE63.22%36.78%Net Buying
FENC4.45%95.55%Net SellingNet Selling
FDMT78.75%21.25%Net Buying
PBYI55.88%43.77%Net Selling
TARA48.52%51.48%Net SellingNet Selling

Fate Therapeutics Stock Ownership FAQ

Who owns Fate Therapeutics?

Fate Therapeutics (NASDAQ: FATE) is owned by 88.63% institutional shareholders, 51.56% Fate Therapeutics insiders, and 0.00% retail investors. Redmile Group LLC is the largest individual Fate Therapeutics shareholder, owning 25.71M shares representing 22.44% of the company. Redmile Group LLC's Fate Therapeutics shares are currently valued at $32.14M.

If you're new to stock investing, here's how to buy Fate Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.